Stempoint Capital LP holds a focused book of 70 stocks worth $520.3M as of Q1 2026 (disclosed May 18, 2026, a ~45-day 13F lag). This quarter they opened ENLIVEN THERAPEUTICS INC and trimmed ABIVAX SA. Their largest long position is SCHOLAR ROCK HLDG CORP at 10% of the equity book. They also disclosed $525K in put options (a bearish bet) and $1.6M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1952142/holdings"
Use Arkolith to show STEMPOINT CAPITAL LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
22% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Scholar Rock Hldg Corp COM | $50.9M | 1.04M | 9.8% | ▲+17% Added · +149K sh | |
| 2 | Abivax Sa SPONSORED ADS | $34.9M | 313.8K | 6.7% | ▼−20% Reduced · −78K sh | |
| 3 | Syndax Pharmaceuticals Inc COM | $28.4M | 1.22M | 5.5% | ▼−9.2% Reduced · −124K sh | |
| 4 | Revolution Medicines Inc COM | $27.4M | 281.6K | 5.3% | ▲+354% Added · +220K sh | |
| 5 | Immunovant Inc COM | $18.5M | 746.5K | 3.6% | ▲+16% Added · +102K sh | |
| 6 | Praxis Precision Medicines I COM NEW | $18.1M | 56.3K | 3.5% | ▲+167% Added · +35K sh | |
| 7 | MBX Biosciences Inc COM | $14.9M | 499.5K | 2.9% | ▲+536% Added · +421K sh | |
| 8 | Mineralys Therapeutics Inc COM | $14.4M | 533.4K | 2.8% | ▲+84% Added · +243K sh | |
| 9 | Enliven Therapeutics Inc COM | $14.2M | 363.4K | 2.7% | ▲New New position | |
| 10 | CG Oncology Inc COM | $13.9M | 205.6K | 2.7% | ▲Added Added · +206K sh | |
| 11 | Biohaven Ltd COM | $13.5M | 1.59M | 2.6% | ▲Added Added · +1.6M sh | |
| 12 | Surrozen Inc COM NEW | $13.5M | 525.6K | 2.6% | ▼−15% Reduced · −94K sh | |
| 13 | Roivant Sciences Ltd SHS | $10.7M | 385.8K | 2.1% | ▼−60% Reduced · −581K sh | |
| 14 | Eyepoint Inc COM NEW | $10.5M | 810.8K | 2.0% | ▲+129% Added · +457K sh | |
| 15 | Arcutis Biotherapeutics Inc COM | $9.7M | 413.8K | 1.9% | ▲+84% Added · +189K sh | |
| 16 | Structure Therapeutics Inc SPONSORED ADS | $9.7M | 200.3K | 1.9% | ▼−43% Reduced · −151K sh | |
| 17 | Amylyx Pharmaceuticals Inc COM | $9.3M | 669.7K | 1.8% | ▲+18% Added · +105K sh | |
| 18 | Dyne Therapeutics Inc COM | $9.2M | 506.1K | 1.8% | ▼−39% Reduced · −329K sh | |
| 19 | Edgewise Therapeutics Inc COM | $9.2M | 290.9K | 1.8% | ▼−19% Reduced · −70K sh | |
| 20 | Cytokinetics Inc COM NEW | $8.5M | 129.6K | 1.6% | ▼−12% Reduced · −17K sh | |
| 21 | Spyre Therapeutics Inc COM NEW | $8.5M | 167.6K | 1.6% | ▲+418% Added · +135K sh | |
| 22 | Denali Therapeutics Inc COM | $8.2M | 426.6K | 1.6% | ▲+1.8% Added · +8K sh | |
| 23 | Xenon Pharmaceuticals Inc COM | $8.2M | 140.8K | 1.6% | ▼−60% Reduced · −208K sh | |
| 24 | Celldex Therapeutics Inc New COM NEW | $8.1M | 254.3K | 1.6% | ▲New New position | |
| 25 | Protagonist Therapeutics Inc COM | $7.6M | 72.6K | 1.5% | ▲+22% Added · +13K sh | |
| 26 | Tyra Biosciences Inc COM | $7.4M | 193.2K | 1.4% | ▲New New position | |
| 27 | Dianthus Therapeutics Inc COM | $7.2M | 85.5K | 1.4% | ▲+7.8% Added · +6K sh | |
| 28 | Celcuity Inc COM | $6.9M | 60.1K | 1.3% | ▼−49% Reduced · −58K sh | |
| 29 | Definium Therapeutics Inc COM SHS | $6.2M | 325.5K | 1.2% | ▲New New position | |
| 30 | Bioage Labs Inc COM | $5.9M | 338.7K | 1.1% | ▲New New position | |
| 31 | Newamsterdam Pharma Company ORDINARY SHARES | $5.8M | 180.7K | 1.1% | ▲+147% Added · +108K sh | |
| 32 | Acadia Pharmaceuticals Inc COM | $5.4M | 242.6K | 1.0% | ▲New New position | |
| 33 | Assembly Biosciences Inc COM NEW | $5.1M | 185.4K | 1.0% | ▲+18% Added · +29K sh | |
| 34 | Alumis Inc COM | $5.1M | 229.6K | 1.0% | ▲New New position | |
| 35 | Nurix Therapeutics Inc COM | $4.9M | 315.2K | 0.9% | ▲New New position | |
| 36 | Zura Bio Ltd CLASS A ORD SHS | $4.5M | 753.5K | 0.9% | ▲New New position | |
| 37 | Evommune Inc COM SHS | $4.4M | 193.8K | 0.8% | ▲+184% Added · +126K sh | |
| 38 | Tango Therapeutics Inc COM | $4.2M | 200.9K | 0.8% | ▲Added Added · +201K sh | |
| 39 | Sensei Biotherapeutics Inc COM NEW | $4.2M | 132.9K | 0.8% | ▲New New position | |
| 40 | Relmada Therapeutics Inc COM | $4.2M | 597.4K | 0.8% | ▲New New position | |
| 41 | Erasca Inc COM | $3.9M | 239.9K | 0.7% | ▲New New position | |
| 42 | Johnson & Johnson COM | $3.8M | 15.4K | 0.7% | ▼−56% Reduced · −20K sh | |
| 43 | X4 Pharmaceuticals Inc COM NEW | $3.5M | 850.7K | 0.7% | ▼−5.3% Reduced · −48K sh | |
| 44 | Vaxcyte Inc COM | $3.4M | 59.1K | 0.7% | ▲New New position | |
| 45 | Whitehawk Therapeutics Inc COM | $3.2M | 939.4K | 0.6% | ▼−36% Reduced · −519K sh | |
| 46 | Helix Acquisition Corp III USD CL A ORD SHS | $3.1M | 305.0K | 0.6% | ▲New New position | |
| 47 | Tenax Therapeutics Inc COM NEW | $3.0M | 188.7K | 0.6% | ▲New New position | |
| 48 | Alkermes PLC SHS | $2.8M | 80.5K | 0.5% | ▲Added Added · +80K sh | |
| 49 | Pharvaris N V COM | $2.4M | 86.6K | 0.5% | ▲+48% Added · +28K sh | |
| 50 | Invivyd Inc COM | $2.4M | 1.87M | 0.5% | ▲+89% Added · +885K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | SCHOLAR ROCK HLDG CORP | $588K | 100K |
| PUT · bearish | REVOLUTION MEDICINES INC | $525K | 100K |
| CALL · bullish | TYRA BIOSCIENCES INC | $290K | 100K |
| CALL · bullish | IMMUNOVANT INC | $255K | 100K |
| CALL · bullish | SPDR SERIES TRUST | $164K | 150K |
| CALL · bullish | SYNDAX PHARMACEUTICALS INC | $90K | 150K |
| CALL · bullish | SS SPDR S&P 500 ETF TRUST-USSPY | $86K | 50K |
| CALL · bullish | INVESCO QQQ TR | $74K | 40K |
| CALL · bullish | BOSTON SCIENTIFIC CORP | $13K | 250K |
| CALL · bullish | TERNS PHARMACEUTICALS INC | $8K | 100K |
| CALL · bullish | OLEMA PHARMACEUTICALS INC | $4K | 25K |
| CALL · bullish | EDWARDS LIFESCIENCES CORP | $1K | 10K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 18, 2026 | 84 | $522.3M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 78 | $583.2M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 90 | $499.1M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 54 | $311.6M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 62 | $313.7M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 58 | $400.6M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 | 58 | $334.0M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 13, 2024 | 44 | $340.3M | 13F-HR/A |
| Q1 2024 | Mar 31, 2024 | Aug 9, 2024 | 63 | $378.3M | 13F-HR/A |
| Q4 2023 | Dec 31, 2023 | Feb 13, 2024 | 70 | $374.8M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.